Compare Novo Nordisk A/S (NVO) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Unilever plc — how do they compare? Novo Nordisk A/S trades at $38.6 (market cap $165.31B), while Unilever plc trades at $62.26 (market cap $131.63B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Unilever plc for 112 Days on average.
| NVO | UL | |
|---|---|---|
Market Cap | $165.31B | $131.63B |
Volume | 11,432,838 | 2,978,741 |
Sector | Health | Consumer Staples |
52-Week High | $63.98 | $74.59 |
52-Week Low | $35.29 | $55.05 |
Typical Hold Time | 116 Days | 112 Days |
Enterprise Value | $179.56B | $156.65B |
Dividend Yield | 4.71% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Unilever (UL) trades at $62.26, up 2.1% today, with a bullish technical signal from moving averages. The company shows strong profitability with 18.32% net income margin and 54.56% ROE, though recent earnings have missed expectations in four consecutive quarters. Unilever is undergoing strategic transformation through its $65 billion food business merger with McCormick while focusing on beauty and personal care segments.
The outlook balances strong emerging market exposure and margin improvement against execution risks from the McCormick deal and competitive pressures. Analyst sentiment is mixed with 24% buy ratings, creating opportunity if restructuring delivers promised returns, though regulatory scrutiny and earnings consistency remain key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
